Nuvalent (NUVL) director Srivastava returned to the company 3,444 shares
Insider transactions reported
Sapna Srivastava (director at Nuvalent Inc., NUVL) reported that they returned to the company 3,444 shares, and disposed of 5,146 shares at $124.00 on Jul 15, 2026. After these transactions the filing shows 0 shares held directly and 0 shares held directly.
- Reporting person
- Srivastava Sapna
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Tender of shares in a change of control (U) | Class A Common Stock1, 2 | -5,146 | $124.00 | $638K | 0 direct |
| Jul 15, 2026 | Sale back to the company (D) | Class A Common Stock - Restricted Stock Units3, 4 | -3,444 | - | - | 0 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Sale back to the company (D) | Stock Option (Right to Buy)On 111,436 Class A Common Stock5 | -111,436 | - | - | 0 direct |
Holdings before and after
- Class A Common Stock: 5,146 to 0 direct
- Class A Common Stock - Restricted Stock Units: 3,444 to 0 direct
- Stock Option (Right to Buy): 68,500 to 0 direct
Footnotes from the filing
- 1. Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the Merger Agreement ), by and among (i) Nuvalent, Inc., a Delaware corporation (the Company ), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ( Parent ), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ( Purchaser ), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ( Ultimate Parent ), Purchaser completed a tender offer (the Offer ) to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the Offer Price ), subject to applicable withholding tax.
- 2. (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the Merger ), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
- 3. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.
- 4. Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a Company RSU ) that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.
- 5. Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a Company Stock Option ) that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.
Transaction codes in this filing
- Sale back to the company:
- Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.
FAQ
What did Srivastava report in this NUVL Form 4?
Sapna Srivastava (director at Nuvalent Inc., NUVL) reported that they returned to the company 3,444 shares, and disposed of 5,146 shares at $124.00 on Jul 15, 2026. After these transactions the filing shows 0 shares held directly and 0 shares held directly.
How many NUVL shares does Srivastava hold after this filing?
The filing shows 0 shares held directly, 0 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code D mean on an SEC Form 4?
Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.
Historical context for NUVL
Across the 24 sessions after earlier NUVL headlines, the stock closed higher 14 times and lower 10 times, with a median move of 1.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NUVL | SPY |
|---|---|---|---|
| Jun 24, 2026 | Nuvalent downgraded by Bernstein with a new price target | +0.1% | -0.0% |
| May 27, 2026 | Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC | +2.3% | -0.0% |
| May 22, 2026 | Bernstein initiated coverage on Nuvalent with a new price targetand 1 other headline that session | +0.9% | +0.4% |
| May 7, 2026 | Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | -1.8% | -0.3% |
| Apr 21, 2026 | Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting | -1.0% | -0.7% |
| Apr 20, 2026 | New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 | +0.6% | -0.2% |
Earlier insider filings at NUVL
- Jul 15, 2026Director Oliger Christy J. returned 6,091 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Jul 15, 2026Director Squarer Ron returned 6,281 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Jul 15, 2026Chief Medical Officer Turner Christopher Durant returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Jul 15, 2026Chief Development Officer Noci Darlene returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Jul 15, 2026Officer Lane Benjamin returned 29,433 units of Class A Common Stock - Restricted Stock Units to the company, was granted 7,120 units of Class A Common Stock - Performance Stock Units and returned 7,120 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow NUVL and get a push notification the moment its next story breaks.